US Oncolytic Virus Immunotherapy Market Market Report 2023 to 2030

US Oncolytic Virus Immunotherapy Market Analysis

$ 3999

US Oncolytic Virus Immunotherapy Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oncolytic Virus Immunotherapy is expanding as a result of growing incidence of cancer. This growth is fueling the demand for better therapy solutions, thus, driving the growth of the Oncolytic Virus Immunotherapy market. Some of the key players in the global Oncolytic Virus Immunotherapy Market include Amgen, Inc., Oncolytics Biotech, Inc., Merck & Co., Inc., Transgene Biotek Ltd., Cold Genesys, Inc., SillaJen, Inc., Sorrento Therapeutics Inc., Shanghai Sunway Biotech Co. Ltd., Amgen Inc., TILT Biotherapeutics, Oncorus, Inc., Replimune Group, Inc., and Oncolys BioPharma, Inc.

ID: IN10USHS053 CATEGORY: Healthcare Services GEOGRAPHY: US AUTHOR: Dr. Nensi Savani

Buy Now

US Oncolytic Virus Immunotherapy Market Executive Summary

US Oncolytic Virus Immunotherapy Market is valued at around $159.6 Bn in 2022 and is projected to reach $342.1 Bn by 2030, exhibiting a CAGR of 10% during the forecast period 2023-2030.

Cancer is one of the leading causes of death worldwide, accounting for 10 Mn deaths in 2020 which is nearly 1 in 6 deaths. This has contributed to the growth of the global market for Oncolytic Virus Immunotherapy in recent years. Advances in technologies, improving the efficacy of the treatment, are also driving the market.

As researchers and scientists seek to find new methods for the treatment and management of cancer, Oncolytic Virus Immunotherapy has emerged as one of the most modern therapeutic strategies. This has been especially beneficial because patients with cancer exhibit little to no benefit from the commonly utilized therapeutic approaches. Oncolytic viruses have been investigated in numerous cancer types, and promising outcomes from various clinical trials suggest the growth of Oncolytic Virus Immunotherapy.

Pharmaceutical and biotechnology firms like Biogen, Eli Lilly, and Company, Roche, and Merck & Co., as well as manufacturers of medical devices like GE Healthcare, Siemens Healthineers, and Philips Healthcare, are some of the major players in the Alzheimer's Disease Diagnostics Market.

The major factors expected to rise during the forecasted period are an increased understanding of oncolytic virus immunotherapy and its therapeutic benefits, advancements in imaging technologies, and the rising use of advanced cancer treatments. In the modern day, it has emerged as a promising therapy for the treatment of cancer. Oncolytic viruses combined with radiation, immune checkpoint inhibitors, and chemotherapeutic drugs are being tested in numerous clinical studies by pharmaceutical companies, and these trials are demonstrating significant impacts and advancements in the treatment of cancer, boosting market growth.

Understanding the mechanisms underlying virus multiplication, entrance, induction, and immune response suppression has led to the use of viruses in the treatment of human diseases and the selection of oncolytic viruses for the treatment of certain types of cancer. This will result in charting a new growth path for the market for oncolytic viral immunotherapy. Additionally, oncolytic viruses send out warning signs that help humans develop effective anti-tumor immune responses. The ability to combat immune evasion caused by cancer will drive the oncolytic virus immunotherapy market during the projected time period.

Market Dynamics

Drivers of US Oncolytic Virus Immunotherapy Market:

Growing Incidence and Prevalence of Cancer: Increased prevalence of various types of cancer is expected to project the growth for the Oncolytic Virus Immunotherapy market.

Advancements in Technology: Technological Advancements in treatment methods for cancer providing improved efficacy is propelling the market for Oncolytic Virus Immunotherapy.

Rising Demand for Targeted Therapies: Another important reason fueling the market expansion for Oncolytic Virus Immunotherapy is the rising need for targeted medicines. Targeted therapies are being adopted by oncologists more often because they produce better results and have fewer adverse effects than traditional chemotherapy regimens.

Developments in Oncolytic Virus Immunotherapy Market:

In 2022, Siga Technologies announced a preclinical collaboration with Bioarchitech for developing immunotherapy for cancer treatments. The research collaboration investigates the TPOXX (tecovirimat) in combination with Bioarchitech’s proprietary vaccinia-based immunotherapy platform which utilizes engineered antibodies and other proteins within the genome of the oncolytic virus.

Key players

Amgen Inc. Merck & Co., Inc. Targovax PsiOxus Therapeutics Oncorus, Inc. Genelux Corporation Replimune Group Inc. ViroCure Virttu Biologics Limited Vyriad, Inc.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For US Oncolytic Virus Immunotherapy Market

By Type:

Vaccinia Virus-based Oncolytic Viruses
Herpes Simplex Virus
HSV-based Oncolytic Viruses
Adenovirus-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses
Others

By Application:

Non-Small Cell Lung Cancer (NSCLC)
Melanoma
Breast Cancer
Pancreatic Cancer
Prostate Cancer
Ovarian Cancer
Myeloma
Bladder Cancer
Others

By Route of Administration:

Intravenous
Intratumoral
Others

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By End-user:

Clinic
Hospital
Cancer Research Institute
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.